Advancing regenerative medicine with RNA nanotechnology for chronic and end organ diseases
Therapies for chronic and end-organ diseases are often associated with systemic toxicity, and such conditions result in difficulty treating patients. RNA nanomedicine has demonstrated unprecedented advantages in the field of therapeutics through its selective organ targeting, personalized treatment option and safety. In this paper, we extensively discuss the current state of nanotechnology in regenerative medicine and how this unique combination of RNA nanomedicine and regenerative medicine can be leveraged for a successful end-organ and chronic disease therapy. More specifically, we have put forward strategies to specifically deliver RNA nanomedicine to target organs/tissues in chronic disease patients, design considerations for regenerative medicine RNA therapy versus RNA vaccines, and barriers to clinical translation. We further discuss the call to action short- and long-term goals in the field of regenerative RNA nanomedicine that could change the face of regenerative medicine in the coming years.
Authors
- S. Hedtrich
- Anita K. Bakrania (ORCID: https://orcid.org/0000-0002-8487-3946)
- Elmar Jaeckel (ORCID: https://orcid.org/0000-0003-4108-7192)
- Michael V. Sefton (ORCID: https://orcid.org/0000-0002-3553-6732)
- Mamatha Bhat (ORCID: https://orcid.org/0000-0003-1960-8449)
- Housheng Hansen He (ORCID: https://orcid.org/0000-0003-2898-3363)
- Laszlo Radvanyi (ORCID: https://orcid.org/0000-0003-1603-3547)
- Anna K. Blakney (ORCID: https://orcid.org/0000-0002-5812-9689)
- Michael A. Laflamme (ORCID: https://orcid.org/0000-0001-5908-880X)
- Anh-Thu Nguyen Lefebvre
- Bowen Li
- Rienk de Vries
- Gaurav Sahay
Institutions
- Ontario Institute for Cancer Research (CA)
- Oregon State University (US)
- University Health Network (CA)
- University of British Columbia (CA)
- Oregon Health & Science University (US)
- University of Toronto (CA)
- Max Delbrück Center (DE)
- Lunenfeld-Tanenbaum Research Institute (CA)
- Toronto Rehabilitation Institute (CA)
- Toronto General Hospital (CA)
- Princess Margaret Cancer Centre (CA)
- Humboldt-Universität zu Berlin (DE)
- Canada's Michael Smith Genome Sciences Centre (CA)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Donner Canadian Foundation (CA)
- Toronto General Hospital Research Institute
- Stem Cell Network (CA)
Publication Details
- Journal
- Communications Medicine
- Published
- 2026-04-11
- DOI
- https://doi.org/10.1038/s43856-026-01476-y
- Primary Topic
- Pluripotent Stem Cells Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00